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BACKGROUND: The association between cancer, major surgery and venous thromboembolism (VTE) is well established. Multimodal
therapy is increasingly being used as standard treatment for localised gastrointestinal cancer. The aim of this study was to examine the
markers of pro-coagulation response and VTE risk in an exemplar multimodal model of pre-operative combination chemotherapy
and radiation therapy, followed by complex cancer surgery.
METHODS: Consecutive patients (n¼36) with localised oesophageal cancer were studied at baseline after the first and second cycles
of chemoradiation, and on post-operative days 1–28, and at 3, 6 and 9 months. Factors regulating the pro- and anti-coagulant
response, as well as pro-inflammatory markers including NFkB activation in peripheral blood mononuclear cells, were examined. All
patients received enoxaparin 40mg s.c. postoperatively up to discharge, and underwent pulmonary CT-pulmonary angiography and
venography on day 10 postoperatively.
RESULTS: Four (11%) non-fatal thromboembolic events were documented, all after hospital discharge. Neoadjuvant therapy before
surgery activated factor VIII (FVIII) and pro-inflammatory NFkB, and increased D-dimers, pro-thrombin fragment 1þ2 (F1þ2) and
the thrombin-anti-thrombin complex (TAT). Surgery significantly (Po0.05) increased pro-thrombin time (PT), activated partial
thromboplastin time, fibrinogen, D-dimers, TAT, F1þ2 and FVIII up to 6 months.
CONCLUSION: These data highlight the linked pro-coagulant and immunoinflammatory pathways in the multimodal management of
oesophageal cancer, and suggest that the duration of current standard thromboprophylaxis regimens warrants further study.
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The association between cancer and venous thromboembolism
(VTE) was established a long time ago (Behanwala and William-
son, 2009). Trousseau reported the association between phlegma-
sia alba dolens and advanced malignancy in 1865, and James and
Matheson reported the association of VTE with occult malignancy
in 1935 (Trousseau, 1865; Illtyd James and Matheson, 1935). The
odds ratio for VTE in malignant disease is approximately 6.5, and
VTE is the second most common cause of death in cancer patients
(Heit et al, 1999). Cancer is associated with a pro-coagulant
response, particularly through tumour elaboration of tissue factor,
a tumour- and host immune-mediated pro-inflammatory cytokine
response and platelet activation. This may manifest in measures of
blood-clotting activation, including pro-thrombin factors 1 and 2
(F1 and 2), Factor VIII (FVIII:C) and the thrombin-anti-thrombin
(TAT) complex (Hoffman et al, 2001; Rickles and Falanga, 2001;
Zwicker and Furie, 2007). All cancer treatment modalities such as
surgery, chemotherapy and radiation therapy can induce a pro-
coagulant and pro-inflammatory response (Geerts et al, 2001).
Cancer surgery is associated with an approximate doubling of
the VTE risk compared with non-cancer surgery (Rickles and
Levine, 2001). The triad of factors associated with coagulation
postulated by Virchow, including venous stasis, activation of
coagulation and inflammatory pathways, as well as an associated
shift to a pro-coagulant endothelium, are all relevant to cancer
surgery. In a multivariate analysis, five risk factors were identified
and associated with VTE risk in surgical cancer patients: age above
60 years, previous VTE, advanced disease, anaesthesia adminis-
tered longer than 2h and bed rest longer than 3 days (Agnelli et al,
2006). Previous studies carried out up to 4 weeks postoperatively
showed an ongoing activation of coagulation (Galster et al, 2000).
New insights highlight the interaction between the inflammatory
and coagulant response, particularly after surgery, and this
association is underlined by randomised trials that show that
recombinant activated protein C (APC) significantly reduces
sepsis-induced mortality in surgical patients (Bernard et al, 2001;
Vincent et al, 2005).
The model of curative cancer treatment for locally advanced
gastrointestinal cancer is increasingly a multimodal approach, with
neoadjuvant chemotherapy, radiation therapy or a combination of
both before resectional surgery. The treatment model for
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soesophageal cancer is ideal for the study of coagulation and VTE
risk, for several reasons. The patient population is homogeneous,
with an average age above 60 years and a duration of surgery
between 4 and 7h. The magnitude of surgical trauma is relatively
uniform with respect to altered physiology, immune function
and metabolism, with a marked pro-inflammatory cytokine
response and a well-defined high risk of clinical complications
(Enzinger and Mayer, 2003). Finally, neoadjuvant chemotherapy
and radiation therapy may be associated with increased operative
risks, and whether this relates to an altered pro-coagulant
or immune response is unknown (Bosset et al, 1997; Reynolds
et al, 2007).
There are no reported longitudinal studies of pro-coagulant
response, immune response or clinical and subclinical VTE risks in
multimodality treatment regimens, and no study in cancer surgical
patients has evaluated these parameters beyond a month
postoperatively. We report herein that neoadjuvant chemoradia-
tion activates the pro-coagulant response, and that oesophageal
cancer surgery is associated with a sustained activation of the
response for up to 6 months postoperatively. All clinical VTE
events occurred beyond the period of post-operative hospitalisa-
tion, and therefore these data may have implications for the
duration of thromboprophylaxis.
PATIENTS AND METHODS
Patients
All patients with localised disease during the period from July 2006
to June 2007 were included in the study. Patients with biopsy-
proven cancer of the oesophagus or an oesophago-gastric junction
with localised disease determined by computerised tomography of
the neck, thorax and abdomen, and whole-body
18FDG-PET scans,
and considered resectable by the primary surgeon, were eligible.
The inclusion criteria for multimodal therapy, approved by the
institutional review board, are as follows: age o77 years;
satisfactory performance status (ASA 1 or 2; Karnofsky 490%)
and medical fitness for surgery; no previous chemotherapy
or radiation therapy; a leukocyte count greater than 3500 per
cubic millimetre, a platelet count above 100000 per cubic
millimetre; and serum creatinine less than 124mmol per litre
(Reynolds et al, 2007).
The multimodality regimen was as previously described, with
radiation (40–44Gy per 15–22 fractions) over 3 weeks, and
concurrent chemotherapy with 5-fluorouracil (15mgkg
 1) on days
1–5 and with cisplatin (75mgm
 2) on day 7; chemotherapy was
repeated on week 6 (Reynolds et al, 2007). All patients underwent a
thoracotomy as a part of their surgical management, either
combined with an abdominal and neck exploration (three-stage)
for mid- and upper-oesophageal cancers, or for cancer arising in
the long-segment Barrett’s oesophagus, or with an abdominal
exploration (two-stage) for most lower third and junctional
tumours, or combined with a total gastrectomy for junctional
tumours with significant gastric extension. A two-field lymphade-
nectomy (abdominal and thoracic) was performed in all cases.
All patients underwent VTE prophylaxis with enoxaparin
sodium (Clexane) 40mg s.c. daily (sanofi aventis, Dublin, Ireland)
only during hospitalisation for surgery. This was commenced at
least 24h before surgery and continued until discharge. All
patients were fed through a needle-catheter jejunostomy, begin-
ning on the first post-operative day, and continuing for
a minimum of 10 days.
Study design
Even in patients with adequate prophylaxis, studies suggest that
outpatient VTE is more common than inpatient VTE after surgery,
thereby challenging existing standards in VTE prophylaxis. We
hypothesise that this is because of prolonged activation of the pro-
coagulant response. The aim of this study was to prospectively
examine the pro-coagulant and inflammatory response up to 9
months postoperatively in a cohort of patients treated with a
multimodal regimen and curative intent for oesophageal cancer.
The institutional review board approved this study. Thrombophilia
testing (anti-thrombin activity, protein C activity, free and total
protein S antigen, APC resistance, factor V Leiden mutation,
Prothrombin 20210 mutation, anti-phospholipid antibody screen)
was performed in all patients. In addition, each patient had the
following studies conducted at baseline, after 1 week of
chemoradiation and after the second cycle of chemotherapy, on
pre-operative day 1 and postoperatively on days 1, 3, 7, 14, 21, 28,
and at 2-, 3-, 6- and 9-month’ follow-up: pro-thrombin time (PT),
activated partial thromboplastin time (APTT), fibrinogen, FVIII,
anti-thrombin, protein C, protein S, D-dimer, TAT complexes
and pro-thrombin fragment 1þ2 (F1þ2) levels, a panel of
cytokines and growth factors. NFkB activation in peripheral blood
mononuclear cells (PBMCs) was measured up to 2 months
postoperatively.
Pro-coagulant studies
Blood was added to tubes containing 0.109 M trisodium citrate
anti-coagulant at a ratio of 9:1, centrifuged (4082r.p.m.) for
20min at 41C, transferred to a pre-chilled tube and stored at
 801C until analysis. Automated functional assays for the
quantitative determination of PT, APTT, protein C and protein S
levels were performed using ACL 9000 Advance Instrumentation
(Beckman Coulter, Dublin, Ireland). FVIII:C was measured by
the one-stage clotting method, using FVIII-deficient substrate
(Immuno, Vienna, Austria), as previously described (O’Donnell
et al, 2001). F1þ2 and TAT complexes were measured using
commercially available ELISA kits (Dade Behring, Marrburg,
Germany). Anti-thrombin antigen levels were determined using
NOR Partigen Immunodiffusion Plates (Dade Behring).
PBMC NFjB activation
Lymphocytes were isolated using Lymphoprep solution (Axis-
Shield, Oslo, Norway). Nuclear and cytoplasmic fractions were
separated, and NFkB and IkBa were measured using the TransAM
kit (Active Motif, Rixensart, Belgium). This assay contains an
immobilised consensus binding site oligonucleotide to which the
activated nuclear extract binds. The positive control used for NFkB
was Jurkat (TPAþCL) nuclear extract. Wild-type and mutated
NFkB consensus oligonucleotides were used to assess the
oligonucleotide-binding specificity of the assay. Addition of
primary antibody specific for either the NFkB p65 or p50 subunit
preceded a series of incubations and washes. A secondary antibody
conjugated to horseradish peroxidase was then added to each well,
subsequently covered and incubated for 1h at room temperature
without agitation, and washed four times with 200ml1  washing
buffer. Finally, developing solution provided a sensitive chemilu-
minescent readout and absorbance was read on the spectro-
photometer at 450nm with a reference wavelength of 655nm.
TransAM Function ELISA (Active Motif, Carlsbad, CA, USA) was
also used for the detection and analysis of IkBa phosphorylation in
cytoplasmic fractions.
Cytokine analysis
Randox Evidence Investigator Biochip (Randox, Belfast, UK) array
technology was used to assay cytokines. This allowed the
simultaneous detection of multiple related cytokine and growth
factors on the basis of immunoassays on a single sample. The
Biochip used is a device containing an array of discrete test regions
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sof immobilised antibodies specific to different cytokines and
growth factors. A sandwich chemiluminescent immunoassay was
used for the cytokine array. The cytokine array was quantitatively
tested for each of the following growth factors and cytokines:
IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IFN-g,T N F - a vascular
endothelial growth factor (VEGF) and epidermal growth factor.
Clinical and radiological assessment
CT pulmonary angiography and venogram (CTPAV) was incorpo-
rated into the staging workup protocol performed on all patients
with oesophageal cancer at the onset of the study. A post-operative
CTPAV was carried out at 10 days in all recruited patients to assess
for asymptomatic thrombus or for the presence of pulmonary
microemboli. Further imaging in search of VTE was performed as
clinically indicated.
All complications from surgery to discharge from hospital were
prospectively documented. Respiratory failure was defined as the
requirement for mechanical ventilation beyond 24h after surgery.
Acute respiratory distress syndrome and multiple organ failure
were as defined by Bone et al (1992). Sepsis required evidence of
SIRS with microbiological evidence of infection, and the diagnosis
of pneumonia required either positive sputum cultures or a clear
clinical and radiographic evidence of consolidation.
Statistical analysis
Statistical analysis was carried out using SPSS version 12 for
Windows (SPSS Inc., Chicago, IL, USA). Primarily, data were
tested for normality. Many of the variables were found to have log-
normal distributions. Therefore, these were transformed using a
log transformation (log10) to run parametric tests on data. For
parametric continuous variables, multiple repeated-measures
analysis of variance (ANOVA) was used to compare the values
preoperatively, with data measured at multiple subsequent time
points. The Friedman test was used to examine changes over time
for data that were not normally distributed. Categorical variables
were compared using cross-tab analysis, and Pearson’s w
2-tests
were used to test for significance. Post-operative values
were compared with those on pre-operative day 1. Values are
mean±s.e.m. Significance was set at Po0.05.
RESULTS
Patient demographics, surgical data and in-hospital
complications
During a 12-month period (July 2006 to June 2007), 36 consecutive
patients with localised oesophageal carcinoma who came to
undergo surgery were enrolled in the study. The mean age was
62 years (range 35–77 years), with 24 men and 12 women. Among
them, –22 patients had adenocarcinoma and 14 had squamous cell
cancer. There was no in-hospital post-operative mortality, 3
patients (8%) had sepsis and 10 (26%) developed pneumonia.
The median post-operative length of stay was 17 days (range,
14–34 days).
Venous thromboembolism
All patients had negative initial screening for thrombophilia. No
VTE was evident following induction chemoradiation before
surgery, or during post-operative hospitalisation. CT pulmonary
angiography and venogram on day 10 postoperatively identified no
subclinical VTE. Four patients (11%) experienced non-fatal clinical
VTE after discharge from hospital. These events were a proximal
DVT (59-year-old man, day 57 postoperatively), bilateral pulmon-
ary emboli (52-year-old man, day 45 postoperatively), a right calf
DVT and bilateral pulmonary emboli (37-year-old man, day 43
postoperatively), and a proximal DVT and unilateral pulmonary
embolus (54-year-old man, day 68 postoperatively).
Neoadjuvant chemoradiation before surgery
Compared with baseline, both the first cycle of combination
chemoradiation and the second cycle of chemotherapy resulted in
significant (Po0.05) increases in FVIII:C, D-dimers, TAT, F1þ2
and NFkB activation (p50) (Table 1). In contrast, significant
(Po0.05) reductions were observed in PT, APTT and protein S
levels. For cytokines and growth factors, there was a significant
(Po0.05) increase in IL-8 after the first cycle of CRT only, and a
significant increase in IL-6 after both cycles. There was a
significant reduction in VEGF after induction chemoradiation
and after the second cycle of chemotherapy. All parameters had
returned to values not significantly above baseline when tested the
day before surgery.
Post-operative responses
Pro-coagulant response D-dimers were significantly (Po0.0001)
increased compared with pre-operative levels at all time points up
to 3 months postoperatively (Figure 1A). There was no significant
change in PT at any time point (Figure 1B); however, APTT was
significantly (Po0.05) increased up to day 60 postoperatively
(Figure 1C), returning to baselines levels thereafter. Factor VIII
(VIII:C) was significantly (Po0.05) increased up to 6 months
postoperatively (Figure 2A). The thrombin-anti-thrombin complex
(Figure 2B) and F1þ2 (Figure 2C) were significantly (Po0.05)
increased up to days 7 and 21, respectively.
Anti-coagulant response A significant (Po0.05) decrease in
plasma anti-thrombin, protein C and protein S levels was observed
on days 1 and 3 postoperatively, compared with pre-operative
day 1 (Figure 3). However, these levels had all returned to baseline
values by day 14.
Immunoinflammatory response Of the 14 cytokines and growth
factors measured, IL- 6, IL-8 and VEGF showed consistent and
Table 1 Neoadjuvant chemoradiation before surgery
Procoagulant Baseline First cycle Second cycle
D-Dimers (ngml
 1) 629±59.02 748±48.35
a 1023±129.68
a
Pro-thrombin time (s) 15±1.08 14±0.77 13±1.05
APTT (s) 32±1.02 30±0.83
a 29±0.91
a
Fibrinogen (gl
 1) 4.19±0.67 4.59±0.20 4.35±0.19
Factor VIII (IUml
 1) 1.80±0.11 2.29±0.21
a 2.71±0.30
a
Thrombin-anti-thrombin
(TATC) (mgml
 1)
6.22±0.05 7.61±0.05
a 8.21±0.06
a
Pro-thrombin fragments
1 and 2 (IUml
 1)
285.29±3.6 297.46±2.8
a 347.62±11.6
a
Anticoagulant
Protein C (IUml
 1) 1.06±0.05 1.01±0.05 1.05±0.06
Protein S (IUml
 1) 0.98±0.06 0.88±0.03
a 0.90±0.05
a
Anti-thrombin (IUml
 1) 1.02±0.03 1.03±0.03 1.05±0.04
Platelets (10
9l
 1) 267±23.6 207±16.8
a 219±34.9
Cytokines and growth factors
IL-6 (pgml
 1) 4.13±1.08 7.60±1.07
a 9.61±1.25
a
IL-8 (pgml
 1) 70.82±34.95 117±5.21
a 71.24±15.35
IL-10 (pgml
 1) 1.09±0.22 0.64±0.19 0.83±0.17
VEGF (pgml
 1) 381±67.4 295±65.4
a 286±60.9
a
NFkB activation
(p50)(OD450nm)
1.27±0.13 1.71±0.17
a 1.75±0.12
a
Abbreviation: APTT¼activated partial thromboplastin time.
aPo0.05 compared
with baseline.
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sreliable measurements in this model. Following oesophagectomy,
there were significant (Po0.05) elevations of IL-6 from baseline
pre-operative levels noted in both cohorts on day 1 and the
increase in IL-6 was sustained up until 1 month post-operatively
(Figure 4A). Levels of IL-8 were not significantly altered
postoperatively (Figure 4B). Vascular endothelial growth factor
levels were significantly (Po0.05) increased in both cohorts up to
3 months postoperatively, and there was no difference between
the two cohorts (Figure 4C). Activation of NFkB p50 was
manifest in the post-operative period, with significant
(Po0.0001) increases from baseline levels recorded throughout
the first week (Figure 5).
DISCUSSION
There is an intriguing association between cancer and VTE, with
increased risks of VTE in patients with cancer, a high prevalence of
occult cancer in patients presenting with idiopathic VTE, and some
evidence that anti-coagulation can affect cancer biology and
improve outcomes (Kakkar et al, 2004; Lee et al, 2005; Behanwala
and Williamson, 2009). Although Virchow and Trousseau,
respectively, provided insights into the pathophysiology of VTE
and its association with cancer in the mid-nineteenth century,
significant gaps exist in the understanding of cancer-associated
VTE. Most scientific research is limited to studies on patients with
advanced malignancies, rather than on patients undergoing
curative approaches, and there is little scientific and clinical
understanding of the impact of multimodal curative approaches.
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Figure 1 (A) D-Dimers were significantly elevated (*Po0.0001) in the
early post-operative period (days 1–7), compared with pre-operative
baseline, and remained elevated up to 3 months postoperatively before
returning to baseline (normal range, 0–300ngml
 1). (B) No significant
difference in pro-thrombin time was observed at any post-operative time
point (P¼NS) (normal range, 12–15s). (C) Activated partial thrombo-
plastin time (APTT) was significantly (*Po0.05) elevated postoperatively
and remained significantly elevated up to post-operative day 60 (normal
range, 25–35s).
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Figure 2 (A) A significant elevation in Factor VIII:C was observed in the
early post-operative period (*Po0.05), and this level remained elevated up
to 6 months postoperatively (normal range, 0.55–2.05IUml
 1). (B) The
thrombin-anti-thrombin (TAT) complex was significantly increased in the
early post-operative period (*Po0.05 up to day 7) but returned to
baseline levels thereafter (normal range, 1–4.1mgml
 1). (C) Pro-thrombin
factor F1þ2 was also significantly elevated postoperatively compared with
pre-operative baseline (*Po0.05), and remained significantly elevated up
to day 14 postoperatively (normal range, 0.24–1.44nmoll
 1).
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sMoreover, there is emerging consensus that the lack of application
of appropriate thromboprophylaxis in cancer patients may
underlie significant morbidity and mortality. The ENDORSE
(Epidemiological International Day for the Evaluation of Patients
at Risk for VTE in the Acute Hospital Care Setting) study included
19842 surgical patients, of whom only 11613 (58.5%) received
American College of Chest Physicians (ACCP)-recommended
thromboprophylaxis (Cohen et al, 2008). Recent studies suggest
that, even in patients with adequate prophylaxis, outpatient VTE is
more common than inpatient VTE after surgery, thereby challen-
ging the existing standards in VTE prophylaxis (Spencer et al,
2007). To the best of our knowledge, this is the first study to
systematically follow through a cohort of patients treated with a
multimodal regimen and curative intent. The finding of an
activated pro-coagulant response after induction chemoradiation
and a sustained response for up to 6 months postoperatively
suggests that trials evaluating extended VTE prophylaxis beyond
current standards should be considered.
Oesophagectomy is an exemplar model of complex major
surgery; there is no common elective oncological resection that
carries the same operative risks, with a 10 and 14% in-hospital
mortality rate reported from recent North American and UK
series, respectively (Bailey et al, 2003; Enzinger and Mayer, 2003;
McCulloch et al, 2003). After the period of post-operative
hospitalisation, a further 20–40% of patients treated with curative
intent die within 1 year (Enzinger and Mayer, 2003). In many
cases, cancer recurrence will clearly be the cause of death, but VTE,
both evident and silent, may be causative, particularly in cases in
which death occurs in the absence of obvious disease recurrence.
In this study, the incidence of symptomatic VTE was 11%.
Screening for subclinical VTE was not continued after post-
operative day 10 within the design of this study. Inherited
thrombophilia was excluded in all patients. In this study, all
patients received post-operative VTE prophylaxis with high-dose
low-molecular-weight heparin (LMWH), and this was continued
for a median of 17 days with a range of 14–34 days. The median
duration of thrombophylaxis in the majority of patients was
shorter than the 28 days supported by the ENOXACAN II and
FAME trials (Bergqvist et al, 2002; Rasmussen et al, 2006). These
positive studies compared short-course with 1-month VTE
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Figure 3 The levels of the natural anti-coagulants, anti-thrombin (normal
range, 0.83–1.15IUml
 1)( A), protein C (normal range, 0.74–
1.32IUml
 1)( B) and protein S (normal range, 0.74–1.32IUml
 1)( C)
were all significantly (*Po0.05) decreased in the early post-operative
period (days 1–7) but returned to normal levels after post-operative day 7.
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Figure 4 Cytokine analysis was performed using the Randox Evidence
Investigator biochip arrays. (A) IL-6 levels were significantly (*Po0.05)
increased in the immediate post-operative period (days 1 and 3), but the
levels returned to normal by post-operative day 7; (B) there was no
significant change in post-operative IL-8 expression (P¼NS); (C) VEGF
levels were significantly (Po0.05) elevated postoperatively up to post-
operative day 28, after which the levels declined.
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sprophylaxis and evaluated clinical and subclinical VTE events in
the first month postoperatively, and the ENOXACAN II study
revealed an approximate 60% reduction in VTE events with the
longer prophylaxis that persisted at 3 months of follow-up
(Bergqvist et al, 2002). In this study, no clinical or silent VTE
was evident by CTPAV on postoperative day 10. It is noteworthy
that all clinical VTE events occurred in the second and third
months postoperatively. In the laboratory analysis, the early
inhibition of the anti-coagulant response, and some elements of an
activated pro-coagulant response, including F1þ2 and TAT,
returned to normal before discharge. Therefore, these increases
may be an acute response to the surgical insult, and it is possible
that they are not related to long-term pro-coagulant activation in
this cohort. However, D-dimers and FVIII:C, for 3 and 6 months,
respectively, persisted during a period when patients were not
receiving VTE prophylaxis, and during which the clinical events
occurred. The proof of concept that this pro-coagulant profile
translates to a risk of VTE in patients after oesophageal or other
complex cancer surgery requires further study; nonetheless, we can
speculate that this inference is reasonable as FVIII:C is associated
with an increased risk of VTE. In a study of 19237 adults with no
baseline history of VTE, cancer or warfarin use, 159 VET events
occurred and elevated FVIII:C levels were common, independent
and dose-dependent risk factors for VTE (Tsai et al, 2002).
The clinical relevance of a sustained post-operative pro-
coagulant response is that recent evidence indicates that outpatient
VTE is three-fold more common than inpatient VTE, and
approximately half of the outpatients with VTE were recently
hospitalised (Spencer et al, 2007). In this study, all VTE episodes
were in the outpatient setting, in patients who were not on LMWH
prophylaxis. As the majority of VTE events occur in the outpatient
setting and the pro-coagulant markers remained elevated for up to
6 months in this study, extension of prophylaxis after discharge
may be warranted in this and other high-risk models. However, the
logistics of such studies are daunting, as a randomised trial
comparing 1 month with 3 months of VTE prophylaxis, with
significant power to reveal a 20% reduction in clinical VTE events
(from 11 to 8.8%), would require 3000 patients per treatment
arm. Studies powered to include subclinical events and surrogate
pro-coagulant markers may have acceptable rationale and less
logistical difficulties.
The design of the study allowed us to address the impact of
neoadjuvant chemoradiation on pro-coagulant response before
surgical resection. Radiotherapy and chemotherapy may contri-
bute to pro-thrombotic risk (Kuzel et al, 1990; Holm et al, 1996;
Tufia et al, 2006). Chemotherapy, including drugs cisplatin and
fluorouracil used in the multimodality regimen, can induce
thrombogenic effects through multiple mechanisms, including
tumour cell secretion of immunomodulatory and pro-angiogenic
cytokines, increased tissue factor expression on vascular endothe-
lial cells, direct vascular endothelial toxicity and reduced protein C
(Kuzel et al, 1990; Tufia et al, 2006) In this study, an upregulated
pro-coagulant response was evident even after 1 week of
combination chemoradiation, associated with elevated FVIII:C,
F1þ2 and TAT levels, with a corresponding reduction in protein C.
These patients did not receive VTE thromboprophylaxis, and no
clinical episodes of VTE were recorded. Hence, the clinical
relevance before surgery is unclear. In addition, whether this
pro-coagulant effect translates into a heightened post-operative
response compared with a group undergoing surgery alone may
merit study. Recent reports indicate that VTE may occur after
radical chemoradiation in patients with advanced oesophageal
cancer, and that this is associated with decreased overall survival
(Tetzlaff et al, 2007, 2008).
A cross talk between inflammation and coagulation was
suggested by the findings of this study. Cytokines associated with
inflammation, in particular TNF-a and IL-1, have been shown to
decrease plasma levels of critical anti-coagulant proteins, including
anti-thrombin and protein C, and to increase tissue factor
expression (Esmon, 2005). Furthermore, APC, which can reverse
these effects in sepsis, works in part through the inhibition of
NFkB activation in inflammatory cells. In this study, the increase
in NFkB and decrease in protein C were matched in the early
response to surgery.
In conclusion, this prospective longitudinal study showed that
induction chemoradiation induced a pro-coagulant and inflam-
matory response, and that sustained pro-coagulation was evident
for 3–6 months postoperatively. The entire period of the multi-
modal regimen, and perhaps up to 6 months afterwards, may
represent a high-risk period for VTE. Scientific and clinical studies
in this model and in other long and complex multimodal regimens
merit further investigation, in particular to address the duration of
appropriate thromboprophylaxis. The relatively low rate of clinical
VTE in this study suggests that subclinical events and surrogate
markers should be included in the design of such studies.
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